Silverback Therapeutics (NASDAQ:SBTX) Hits New 1-Year High – Still a Buy?

Silverback Therapeutics, Inc. (NASDAQ:SBTXGet Free Report) shares reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $15.38 and last traded at $14.27, with a volume of 890970 shares. The stock had previously closed at $15.17.

Silverback Therapeutics Price Performance

The stock has a market capitalization of $514.55 million, a PE ratio of -6.27 and a beta of 0.60. The business has a 50 day moving average price of $13.74 and a 200 day moving average price of $11.04.

Silverback Therapeutics Company Profile

(Get Free Report)

Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.

Featured Articles

Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.